LEXICON PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $91.7M | $79.3M | $130.0M | $22.9M | $2.2M | $1.1M | $1.8M | $4.9M |
| Cost of Revenue | $1.9M | $0 | $0 | — | — | — | — | — |
| Gross Profit | $89.8M | $79.3M | $130.0M | — | — | — | — | — |
| Gross Margin | 97.9% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $152.2M | $164.0M | $95.2M | $89.3M | $89.7M | $82.6M | $91.8M | $78.5M |
| SG&A Expense | $66.1M | $43.2M | $23.8M | $19.4M | $17.1M | $17.0M | $17.4M | $19.4M |
| Operating Income | $-130.6M | $-127.2M | $1.5M | $-100.4M | $-102.4M | $-108.4M | $-114.1M | $-95.7M |
| Operating Margin | -142.5% | -160.5% | 1.1% | -439.2% | -4,607.2% | -9,955.5% | -6,170.6% | -1,950.2% |
| Interest Expense | $7.0M | $6.6M | $6.7M | $2.3M | $2.0M | $2.1M | $2.5M | $2.7M |
| Pretax Income | $-135.7M | $-131.4M | $-4.7M | $-100.4M | $-104.1M | $-110.2M | $-116.2M | $-101.8M |
| Income Tax Expense | — | $0 | $0 | $-70.0K | $0 | $0 | $0 | $-26.0K |
| Net Income | $-123.0M | $-131.4M | $-4.7M | $-100.3M | $-104.1M | $-110.2M | $-116.2M | $-101.8M |
| Net Margin | -134.1% | -165.8% | -3.6% | -438.8% | -4,686.1% | -10,120.4% | -6,285.3% | -2,073.7% |
| EPS (Basic) | $-1.17 | $-1.27 | $-0.05 | $-1.31 | $-1.42 | $-0.23 | $-0.34 | $-0.34 |
| EPS (Diluted) | $-1.17 | $-1.27 | $-0.05 | $-1.31 | $-1.42 | $-0.23 | $-0.34 | $-0.34 |
| Shares Outstanding (Basic) | — | 103.8M | 725.1M | 513.8M | 513.0M | 480.6M | — | — |
| Shares Outstanding (Diluted) | 105.2M | 103.8M | 725.1M | 513.8M | 513.0M | 480.6M | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |